Effect of Advertisements on Treatment Compliance in Women With Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00462410
First received: April 18, 2007
Last updated: January 20, 2012
Last verified: May 2011
  Purpose

RATIONALE: Measuring how advertising affects treatment compliance in women with breast cancer may help doctors plan the best treatment.

PURPOSE: This clinical trial is studying how advertisements affect treatment compliance in women with breast cancer.


Condition Intervention
Breast Cancer
Other: counseling intervention
Procedure: psychosocial assessment and care

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Socio-anthropological Study Evaluating the Impact of Observance or Treatment in Patients With Breast Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Treatment compliance [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Factors affecting adherence to the medical plan [ Designated as safety issue: No ]

Estimated Enrollment: 65
Study Start Date: March 2006
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Evaluate the consequences of advertisement on treatment compliance in women with breast cancer.

Secondary

  • Determine the factors favoring or not favoring adherence to the medical recommendations.

OUTLINE: Patients and their medical and nonmedical caregivers are interviewed by a sociologist or anthropologist twice over 1 year. The first interview is at the consultation visit and the second interview is at the patient's home. The impact of advertisement on treatment compliance is measured.

PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of breast cancer
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Female
  • Menopausal status not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00462410

Sponsors and Collaborators
Institut Bergonié
Investigators
Study Chair: Marc Debled, MD Institut Bergonié
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00462410     History of Changes
Other Study ID Numbers: CDR0000540528, IB-2006-03, INCA-REF0145, INCA-SOCIO-ANTHROPO
Study First Received: April 18, 2007
Last Updated: January 20, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent breast cancer
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on October 16, 2014